ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.650
-0.060 (-3.51%)
At close: Sep 25, 2026, 4:00 PM EDT
1.700
+0.050 (3.03%)
Pre-market: Sep 28, 2026, 4:00 AM EDT
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 8.76M EUR in the quarter ending June 30, 2026, with 120.35% growth. This brings the company's revenue in the last twelve months to 18.42M, up 7.49% year-over-year. In the year 2025, ProQR Therapeutics had annual revenue of 16.35M, down -16.36%.
Revenue (ttm)
18.42M EUR
Revenue Growth
+7.49%
P/S Ratio
11.06
Revenue / Employee
98,730 EUR
Employees
187
Market Cap
232.85M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.35M | -3.20M | -16.36% |
| Dec 31, 2024 | 19.55M | 10.02M | 105.20% |
| Dec 31, 2023 | 9.53M | 5.17M | 118.51% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | -7.07M | -74.84% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Compugen | 74.00M |
| Cue Biopharma | 37.66M |
| Keros Therapeutics | 15.01M |
| Pyxis Oncology | 11.04M |
| Entrada Therapeutics | 4.69M |
| Cartesian Therapeutics | 1.48M |
| Lyell Immunopharma | 27.00K |
PRQR News
- 4 days ago - ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor - GlobeNewsWire
- 18 days ago - ProQR Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 18 days ago - ProQR Therapeutics doses first participant in AX-0811 clinical trial - TheFly
- 18 days ago - ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 - GlobeNewsWire
- 25 days ago - ProQR to Participate in Upcoming Investor Conferences in September 2026 - GlobeNewsWire
- 5 weeks ago - ProQR Therapeutics initiated with a Buy at BofA - TheFly
- 6 weeks ago - ProQR Announces Second Quarter 2026 Operating and Financial Results - GlobeNewsWire
- 6 weeks ago - ProQR Therapeutics Earnings release: Q2 2026 - Filings